Hi Neil,
If and when i see such a post, i will be certain to draw that posters attention to more recent and relevant issues.
I am sure you can understand, with your ceaseless spruiking of the stock, it may have appeared to some posters that you are on a "payroll", just as those who are ceaseless in their criticisms may appear to be "paid downrampers of the pharmaceutical industry".
But you have cleared that up, so if i see such a question asked, i will be confident to reply to their post and ensure they are informed of the current status, that Neil is not a current employee of the company, nor a subcontractor, nor has any other business affiliation, just a passionate social media poster with a vested interest of being a shareholder.
So i shall consider this point, clarified ad nauseum, and no longer needing to be rehashed.
P.s Neil, can you please kindly advise where the company and/or the ASX had announced this approval, prior to the 15th of May 2019 announcement?
"The ASX had already approved the company to relist without the added Directors before the investigation. "
- Forums
- ASX - By Stock
- CGB
- Ann: Preliminary Final Report
Ann: Preliminary Final Report, page-68
-
-
- There are more pages in this discussion • 91 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CGB (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online